CN111686199A - Anti-fatigue Chinese wolfberry composition - Google Patents
Anti-fatigue Chinese wolfberry composition Download PDFInfo
- Publication number
- CN111686199A CN111686199A CN202010620675.1A CN202010620675A CN111686199A CN 111686199 A CN111686199 A CN 111686199A CN 202010620675 A CN202010620675 A CN 202010620675A CN 111686199 A CN111686199 A CN 111686199A
- Authority
- CN
- China
- Prior art keywords
- parts
- fatigue
- product
- mice
- royal jelly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 230000002929 anti-fatigue Effects 0.000 title claims abstract description 18
- 244000241872 Lycium chinense Species 0.000 title description 3
- 235000015468 Lycium chinense Nutrition 0.000 title description 3
- 229940109850 royal jelly Drugs 0.000 claims abstract description 20
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 16
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 16
- 235000017784 Mespilus germanica Nutrition 0.000 claims abstract description 15
- 244000182216 Mimusops elengi Species 0.000 claims abstract description 15
- 235000000560 Mimusops elengi Nutrition 0.000 claims abstract description 15
- 235000007837 Vangueria infausta Nutrition 0.000 claims abstract description 15
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 15
- 235000011477 liquorice Nutrition 0.000 claims abstract description 15
- 241000005787 Cistanche Species 0.000 claims abstract description 14
- 229920002527 Glycogen Polymers 0.000 claims description 17
- 210000004369 blood Anatomy 0.000 claims description 17
- 239000008280 blood Substances 0.000 claims description 17
- 229940096919 glycogen Drugs 0.000 claims description 17
- 239000000463 material Substances 0.000 claims description 11
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 claims description 10
- 210000004185 liver Anatomy 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 11
- 239000002994 raw material Substances 0.000 abstract description 11
- 229960003080 taurine Drugs 0.000 abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 35
- 241000699670 Mus sp. Species 0.000 description 34
- 230000009182 swimming Effects 0.000 description 25
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- 235000019441 ethanol Nutrition 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 13
- 239000003814 drug Substances 0.000 description 11
- 206010016256 fatigue Diseases 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- 239000004310 lactic acid Substances 0.000 description 9
- 235000014655 lactic acid Nutrition 0.000 description 9
- -1 etc.) Polymers 0.000 description 8
- 239000000843 powder Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000010298 pulverizing process Methods 0.000 description 4
- 238000003809 water extraction Methods 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 231100000403 acute toxicity Toxicity 0.000 description 3
- 230000007059 acute toxicity Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000336291 Cistanche deserticola Species 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000034659 glycolysis Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- BSYNFGPFPYSTTM-UHFFFAOYSA-N 2-hydroxypropanoic acid;hydrate Chemical compound O.CC(O)C(O)=O BSYNFGPFPYSTTM-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 241000756042 Polygonatum Species 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000004099 anaerobic respiration Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000037080 exercise endurance Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000037360 nucleotide metabolism Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- UAEJRRZPRZCUBE-UHFFFAOYSA-N trimethoxyalumane Chemical compound [Al+3].[O-]C.[O-]C.[O-]C UAEJRRZPRZCUBE-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L21/00—Marmalades, jams, jellies or the like; Products from apiculture; Preparation or treatment thereof
- A23L21/20—Products from apiculture, e.g. royal jelly or pollen; Substitutes therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/64—Orobanchaceae (Broom-rape family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Insects & Arthropods (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides an anti-fatigue composition, which comprises the following components: 30-50 parts of medlar, 10-20 parts of rhizoma polygonati, 2-8 parts of royal jelly, 2-8 parts of cistanche and 2-8 parts of liquorice. The invention combines and uses all raw materials, has good anti-fatigue activity, and has more unexpected activity than taurine.
Description
Technical Field
The invention belongs to the field of natural medicines, foods or health-care foods.
Background
Fatigue is a complex physiological and biochemical process, a protective response of the body to prevent life-threatening excessive failure, the production of which alerts the worker that he should reduce his work intensity or stop exercising in order to avoid damaging the body. With the increasing work pace of people, the relieving and preventing of fatigue are more and more emphasized.
It is generally considered that three mechanisms causing fatigue are exhaustion of energy substances, accumulation of metabolites, and imbalance of homeostasis. When the body moves, energy is obtained mainly by glycolysis of glycogen, when glycogen is consumed in a large amount, lactic acid which is a glycolysis product is accumulated, the content of serum urea nitrogen is greatly increased, and the body can be fatigued. While muscle glycogen is consumed, the body can break down liver glycogen to maintain blood glucose levels, supplementing energy. Once muscle glycogen and liver glycogen are largely consumed, blood glucose drops cause central nervous system function to be insufficient, resulting in the occurrence of systemic fatigue.
Disclosure of Invention
The invention aims to provide a natural product with good anti-fatigue effect.
Specifically, the invention provides an anti-fatigue composition, which comprises the following components: 30-50 parts of medlar, 10-20 parts of rhizoma polygonati, 2-8 parts of royal jelly, 2-8 parts of cistanche and 2-8 parts of liquorice.
The medlar anti-fatigue product is based on the theory of traditional Chinese medicine and takes preventive medicine and nutriology as guidance, and the core raw materials are medlar, rhizoma polygonati, royal jelly, cistanche and liquorice. According to the compatibility theory of 'monarch, minister, assistant and guide' of traditional Chinese and Tibetan medicines, the medlar is monarch, the rhizoma polygonati is minister, the royal jelly and the cistanche are assistant, and the liquorice is guide and harmonized with other medicines, so that the effect of relieving physical fatigue is achieved.
Wherein, it comprises the following components: 40 parts of medlar, 15 parts of rhizoma polygonati, 5 parts of royal jelly, 5 parts of cistanche and 5 parts of liquorice.
The invention also provides an anti-fatigue product, which at least comprises the composition.
Wherein, the product also comprises auxiliary materials or auxiliary components.
Wherein the product is a gastrointestinal absorption product.
The invention can adopt the conventional preparation mode of food, health-care food or medicine when preparing the product.
For example, the raw materials may be prepared into powder and then mixed uniformly.
The royal jelly can be made into lyophilized powder by freeze-drying. Other raw materials can be pulverized by pulverizing equipment, either by ordinary pulverization or by ultrafine pulverization.
Or, other raw materials except for royal jelly can be extracted by conventional methods, such as water extraction, alcohol-water double extraction, water extraction and alcohol precipitation, and the obtained extract is mixed with royal jelly to prepare the product.
Or, the royal jelly, the liquorice and the cistanche deserticola are prepared into powder, and other raw materials are extracted by a conventional method, such as water extraction, alcohol-water double extraction, water extraction and alcohol precipitation and the like, and the obtained extract is combined with the powder of the royal jelly, the liquorice and the cistanche deserticola to prepare the product.
The auxiliary materials are general names of all additional materials except the main medicine in the medicinal preparation, and the auxiliary materials have the following properties: (1) no toxic effect on human body and few side effects; (2) the chemical property is stable and is not easily influenced by temperature, pH, storage time and the like; (3) has no incompatibility with the main drug, and does not influence the curative effect and quality inspection of the main drug; (4) does not interact with the packaging material.
The auxiliary component has certain physiological activity, but the addition of the component does not change the dominant position of the composition in the disease treatment process, but only plays an auxiliary effect, and the auxiliary effects are only utilization of the known activity of the component and are auxiliary treatment modes which are conventional in the field of medicine. If the auxiliary components are used in combination with the composition of the present invention, the protection scope of the present invention should still be included. Such as taurine.
Pharmaceutically acceptable adjuvants, such as cellulose and its derivatives (such as sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as stearic acid, magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerol, mannitol, sorbitol, etc.), and emulsifiers (such as propylene glycol, glycerol, mannitol, sorbitol, etc.)
) Wetting agents (e.g., sodium lauryl sulfate), coloring agents, flavoring agents, stabilizers, antioxidants, preservatives, pyrogen-free water, and the like.
Wherein, the composition is an oral administration preparation.
Of course, the mode of administration of the composition of the present invention is not particularly limited, and topical administration may be used in addition to oral administration.
Solid dosage forms for oral administration include capsules, tablets, pills, powders, granules, bagged steeping agents and the like, and are not limited to the above dosage forms. In these solid dosage forms, the raw material or extract is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following ingredients: (a) fillers or extenders, for example, starch, lactose, sucrose, glucose, mannitol and silicic acid; (b) binders, for example, hydroxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and acacia; (c) humectants, for example, glycerol; (d) disintegrating agents, for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) slow solvents, such as paraffin; (f) absorption accelerators, e.g., quaternary ammonium compounds; (g) wetting agents, such as cetyl alcohol and glycerol monostearate; (h) adsorbents, for example, kaolin; and (i) lubricants, for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In capsules, tablets and pills, the dosage forms may also comprise buffering agents.
Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared using coatings and shells such as enteric coatings and other materials well known in the art. They may contain opacifying agents and the release of the active compound or compounds in such compositions may be delayed in release in a certain part of the digestive tract. Examples of embedding components which can be used are polymeric substances and wax-like substances. If desired, the material or extract may also be in microencapsulated form with one or more of the above excipients.
Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures. In addition to the starting materials or extracts, the liquid dosage forms may contain inert diluents commonly employed in the art, such as water or other solvents, solubilizing agents and emulsifiers, e.g., ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, propylene glycol, 1, 3-butylene glycol, dimethylformamide, and oils, especially cottonseed, groundnut, corn germ, olive, castor and sesame oils, or mixtures of such materials, and the like.
In addition to these inert diluents, the compositions can also contain adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents. In addition to the starting materials or extracts, the suspensions may contain suspending agents, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar, or mixtures of these substances, and the like.
The ethanol used in the invention comprises hydrous ethanol and anhydrous ethanol, the concentration of the hydrous ethanol is 5-95%, and for the raw materials of the invention, 50-95% v/v ethanol is usually used, such as 50-60%, 60-70%, 70-80%, 80-95% and the like. If the method adopts the hydrous ethanol for extraction, the method does not exclude the mode of gradient extraction, namely, firstly extracting by using high-concentration ethanol and then extracting by using low-concentration ethanol, thereby ensuring the complete extraction of the effective components.
The invention also provides the application of the composition or the product in preparing anti-fatigue products.
The invention also provides the application of the composition or the product in preparing products for reducing body lactic acid, blood urea nitrogen or increasing liver glycogen.
The invention also provides application of 30-50 parts of medlar, 10-20 parts of rhizoma polygonati, 2-8 parts of royal jelly, 2-8 parts of cistanche and 2-8 parts of liquorice in preparing an anti-fatigue combined product.
As a combination product, the various products may be produced separately or/and packaged for use either simultaneously or sequentially with a brief time difference.
The term "having a short time difference" in the present invention means that one or more of wolfberry, polygonatum, royal jelly, cistanche and licorice is/are taken within 24 hours. For example, powder or extract of fructus Lycii, rhizoma Polygonati, Cistanchis herba, and Glycyrrhrizae radix is administered first, and Lac Regis Apis is administered within 60min before and after administration, or in the morning and evening respectively.
The combined product can be independently packaged or separately packaged.
Taurine, also known as taurine, is a major functional ingredient of many functional beverages to resist fatigue. The invention combines and uses all raw materials, has good anti-fatigue activity, and has more unexpected activity than taurine.
Detailed Description
Example 1
40g of medlar, 15g of rhizoma polygonati, 5g of royal jelly, 5g of cistanche and 5g of liquorice; pulverizing the above materials, and mixing with lyophilized royal jelly powder.
Example 2
Taking 50g of medlar, 10g of rhizoma polygonati, 8g of cistanche and 8g of liquorice, decocting and extracting for 2-3 times, taking water extract, concentrating, drying, and uniformly mixing with royal jelly freeze-dried powder.
Example 3
Decocting fructus Lycii 50g, rhizoma Polygonati 10g, Cistanchis herba 8g, and Glycyrrhrizae radix 8g with water for 2-3 times, collecting the extractive solution, concentrating, adding Lac Regis Apis 8g, and stirring.
Example 4
Taking 30g of medlar, 20g of rhizoma polygonati, 2g of cistanche and 2g of liquorice, sequentially extracting with 75% ethanol and water for 2-3 times, recovering ethanol from an ethanol extracting solution, combining with a water extracting solution, concentrating, adding 5g of royal jelly, and uniformly stirring.
Example 5
Taking 50g of medlar, 10g of rhizoma polygonati, 8g of cistanche and 8g of liquorice, decocting and extracting for 2-3 times, taking the water extract, and concentrating to prepare a product A. And 8g of royal jelly is taken and filled to be used as a product B.
A and B can be placed under the same outer package.
Test examples
The efficacy of the medlar antifatigue formula in relieving physical fatigue is verified by using experimental mice, and the experimental method is referred to the relevant experimental method of health food inspection and evaluation technical specification (2003 edition).
Test materials and methods
1.1 test materials
The mixture prepared in example 1 (formulation 1 for short) was vacuum packed in aluminum foil.
Taurine particles (positive control), difsa pharmaceutical group ltd.
The whole blood lactic acid, serum urea nitrogen and liver glycogen detection kits are all purchased from Nanjing institute of bioengineering.
ICR mice, each half male and female, weighing 22 g-25 g, were purchased from Jinan Pengyue laboratory animal Breeding Co. License number: SCXK (lu) 20140007. The mice are firstly raised in the animal room for one week, and formal experiments are carried out after the mice are fully adapted to the environment of the animal room. The light and shade of the animal room alternate 12h, and all animals feed water freely.
1.2 test methods
(1) Acute toxicity test of mice
The dose of the acute toxicity of the mice is 1g per day. Formulation 1 was made into a suspension with 0.5% sodium carboxymethylcellulose (CMC) to a final concentration of 0.7g/ml, and the mice were weighed and gavaged at 0.1ml/10g weight 1 time per 3 hours for 6 times. Then, the mice were kept on water for 10 days with normal diet, and the weight change, fur, mental state and defecation of the mice were recorded.
(2) Test grouping
In the fatigue relieving experiment after the acute toxicity experiment, the formula raw materials are uniformly mixed into the raw materials of the mouse feed, and the formula feed is re-prepared according to the daily feed amount of the mouse and is continuously fed for 30 days. Healthy ICR mice were divided into 5 groups (normal control group, positive group, formula 1 low, medium, and high dose groups, converted to adult doses (6 g/day, 9 g/day, and 12 g/day)) at random, and the body weights of the mice were weighed once a week. The heavy-load swimming experiment and the swimming biochemical detection experiment are carried out in 2 batches, and each batch has 6 mice male and female.
The dose conversion method is described in Huang-Ji Han et al, equivalent dose conversion between animals and human bodies in pharmacological tests, Chinese clinical pharmacology and therapeutics, 2004.
(3) Experiment of mouse weight bearing swimming
After 30 days of continuous feeding, the mice were loaded with 5% weight by tying them to their tails with lead wires, and placed in a swimming box, and the time from the beginning of swimming to death of the mice was recorded. The round swimming box has the caliber of 40cm, the water temperature of 25 ℃ and the water depth of more than 30cm, and the exhaustion time is the exhaustion time when the mouse can not keep continuous swimming. The mice were placed in 7 swimming boxes in batches, and the number of swimming mice in each swimming box was 1. Each group of experimental mice had 6 males and females.
(4) Biochemical index determination of mouse swimming:
the mice are put into a swimming box for swimming for 90min, and rest for 60min after water is discharged. Blood is collected by eyeballs before swimming, after swimming and after rest of the mice, and the whole blood lactic acid and serum urea are measured according to the instruction of the kit.
After resting for 60min, mice were dislocated and sacrificed, livers (mass <100mg) were removed and liver glycogen was assayed according to kit instructions.
(5) Data processing and statistical analysis
Experimental data was collected and statistically analyzed using IBM SPSS 19.0. All experimental results, expressed as SD, were statistically analyzed by One-way ANOVA or t-test, with p <0.05 as the difference having statistical significance and p <0.01 as the difference having significant statistical significance.
2 results of the test
2.1 acute toxicity test results
After the ICR mice are orally taken at the dose of 1 g/mouse.
2.2 changes in body weight of mice
The mice were weighed 5 times a week during the 30-day period of the experiment, and the differences in body weight of the mice were found to be insignificant (P >0.05) in each treatment group compared to the control group, as shown in table 1.
TABLE 1 mean body weight (g) of mice
N＝24)
2.3 swimming exhaustion time
The prolongation of exercise endurance is the most powerful evidence of fatigue resistance. The experiment shows that: the mice in the experimental group had longer swimming time than the normal control group, and the mice in the formula 1 and the high-dose group had obvious difference (p <0.05) compared with the control group, which is shown in table 2.
TABLE 2 mouse exhaustive swimming time in seconds
N＝12)
2.4 Whole blood lactate
The amount of lactic acid in the blood can be indicative of the intensity of anaerobic respiration in the body. The blood lactic acid content of each group of mice before swimming is not very different (P is more than 0.05), the blood lactic acid water after swimming is obviously improved on average, and the blood lactic acid of each group of mice is recovered to different degrees after 60min of rest. It can be seen that the mice in the formulation 1 and the high dose group have significant difference compared with the control group (p <0.01), and see table 3.
TABLE 3 change in blood lactic acid value (mmol/L) of mouse: (
N＝12)
2.5 serum Urea Nitrogen
Blood urea nitrogen is a metabolite of an organism during exercise, and is the most common biochemical index for evaluating the fatigue degree of the organism during long-time moderate-intensity exercise or strenuous exercise. During long-term movement of the body, as the decomposition of proteins and amino acids in the body is enhanced, the nucleotide metabolism is also enhanced, and ammonia generated by the decomposition of the amino acids and the nucleotides is converted into urea, so that the blood urea nitrogen level is increased. Formulation 1 the high dose group mice had significantly lower serum urea nitrogen values than the control group (p <0.01), see table 4.
TABLE 4 changes in mouse serum Urea Nitrogen (mmol/L) (II)
N＝12)
2.6 hepatic glycogen
The storage of glycogen is of great importance for maintaining blood sugar level during exercise, while the central nervous system and some body cells (such as red blood cells) can only use sugar as energy source, and the storage amount of glycogen can directly influence the exercise capacity of the body. The experiment proves that the energy substance reserves can be increased to different degrees by a plurality of formulas, and the aim of resisting fatigue is further fulfilled. The experiment shows that: the liver glycogen content of mice in each dose group is higher than that of the control group, and the high dose group has a significant difference (P <0.01) compared with the blank control group, which is shown in Table 5.
TABLE 5 Change in liver glycogen content (mg/100g) of mice after swimming: (
N＝12)
Discussion and summary of 3
The experimental study shows that:
(1) after a single large-dose intragastric administration (1 g/day) of a mouse, the formula has no acute toxicity and is safe.
(2) After the mice were separately gazed with each formula, the time of the swimming exhaustion experiment showed that formula 1 was effective.
(3) The experimental results of the swimming exhaustion can be basically verified and supported by comparing and analyzing the whole blood lactic acid and the serum urea nitrogen before and after swimming, and the middle-high dose of the formula 1 is effective after the swimming of the mice.
(4) The result of detecting the hepatic glycogen shows that the formula 1 can greatly improve the reserve amount of the hepatic glycogen so as to play a good anti-fatigue role.
Claims (8)
1. An anti-fatigue composition characterized by: it comprises the following components: 30-50 parts of medlar, 10-20 parts of rhizoma polygonati, 2-8 parts of royal jelly, 2-8 parts of cistanche and 2-8 parts of liquorice.
2. The anti-fatigue composition according to claim 1, wherein: it comprises the following components: 40 parts of medlar, 15 parts of rhizoma polygonati, 5 parts of royal jelly, 5 parts of cistanche and 5 parts of liquorice.
3. An anti-fatigue product characterized by: comprising at least a composition according to any one of claims 1 or 2.
4. The fatigue resistant product of claim 3, wherein: the product also comprises auxiliary materials or auxiliary components.
5. The fatigue resistant product according to claim 3 or 4, characterized in that: the product is a gastrointestinal absorption product.
6. Use of a composition according to claim 1 or 2 or a product according to any one of claims 3 to 5 in the manufacture of an anti-fatigue product.
7. Use of a composition according to claim 1 or 2 or a product according to any one of claims 3 to 5 in the manufacture of a product for lowering body lactate, blood urea nitrogen or increasing liver glycogen.
8. 30-50 parts of medlar, 10-20 parts of rhizoma polygonati, 2-8 parts of royal jelly, 2-8 parts of cistanche and 2-8 parts of liquorice, and the application thereof in preparing anti-fatigue combined products.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010620675.1A CN111686199A (en) | 2020-07-01 | 2020-07-01 | Anti-fatigue Chinese wolfberry composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010620675.1A CN111686199A (en) | 2020-07-01 | 2020-07-01 | Anti-fatigue Chinese wolfberry composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111686199A true CN111686199A (en) | 2020-09-22 |
Family
ID=72484830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010620675.1A Pending CN111686199A (en) | 2020-07-01 | 2020-07-01 | Anti-fatigue Chinese wolfberry composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111686199A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111588777A (en) * | 2020-07-01 | 2020-08-28 | 珠海琴海生物科技有限公司 | Blood fat reducing wolfberry composition |
| CN114304067A (en) * | 2022-02-03 | 2022-04-12 | 兰州大学 | Method for establishing compound-factor-induced fatigue mouse model and anti-fatigue composition |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1325718A (en) * | 2001-05-24 | 2001-12-12 | 林金平 | Freeze dried compound queen bee powder |
| CN1733144A (en) * | 2005-08-10 | 2006-02-15 | 青海省花宝蜂业股份合作公司 | Capsule comprising Chinese caterpillar fungus, royal jelly and matrimony vine |
| CN104435703A (en) * | 2014-11-04 | 2015-03-25 | 天津大学 | Composition for relieving physical fatigue |
| CN110812445A (en) * | 2019-11-28 | 2020-02-21 | 福州和杏健康管理服务有限公司 | Pharmaceutical composition for preventing and/or treating osteoporosis and preparation method and application thereof |
-
2020
- 2020-07-01 CN CN202010620675.1A patent/CN111686199A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1325718A (en) * | 2001-05-24 | 2001-12-12 | 林金平 | Freeze dried compound queen bee powder |
| CN1733144A (en) * | 2005-08-10 | 2006-02-15 | 青海省花宝蜂业股份合作公司 | Capsule comprising Chinese caterpillar fungus, royal jelly and matrimony vine |
| CN104435703A (en) * | 2014-11-04 | 2015-03-25 | 天津大学 | Composition for relieving physical fatigue |
| CN110812445A (en) * | 2019-11-28 | 2020-02-21 | 福州和杏健康管理服务有限公司 | Pharmaceutical composition for preventing and/or treating osteoporosis and preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 崔同寅: "《识别真假补药吃出健康长寿》", 30 April 2015, 中医古籍出版社 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111588777A (en) * | 2020-07-01 | 2020-08-28 | 珠海琴海生物科技有限公司 | Blood fat reducing wolfberry composition |
| CN114304067A (en) * | 2022-02-03 | 2022-04-12 | 兰州大学 | Method for establishing compound-factor-induced fatigue mouse model and anti-fatigue composition |
| CN114304067B (en) * | 2022-02-03 | 2024-01-09 | 兰州大学 | Method for establishing compound factor fatigue-induced mouse model and anti-fatigue composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106135891A (en) | A kind of health food to alcoholic liver injury with defencive function | |
| CN105596702A (en) | Traditional Chinese medicine composition with sleep improving function | |
| CN111686199A (en) | Anti-fatigue Chinese wolfberry composition | |
| CN104432063B (en) | Composition for alleviating athletic fatigue and preparation method thereof | |
| KR20190023091A (en) | Perilla extract composition | |
| CN101143202B (en) | Compound oral administration preparation with protective function to chemical liver injury | |
| WO2021109511A1 (en) | Anti-fatigue composition and preparation method therefor | |
| CN105769970A (en) | Siraitia grosvenorii chewable tablets and preparation method thereof | |
| CN101879264A (en) | Chinese medicinal composition for reducing blood uric acid | |
| CN101011432B (en) | Use of extract of bracken flavone as medicament for lead expelling and lead poisioning alleviation | |
| CN101099753A (en) | Preparation method and application for general saponin of cortex ilecis rotundae | |
| CN117018125B (en) | Anti-fatigue pharmaceutical composition | |
| CN112007124B (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating or preventing hyperlipidemia | |
| CN107551001A (en) | A kind of Chinese herbal compounds and its preparation method for being used to prevent and treat alcoholic liver injury | |
| CN106924270B (en) | Orlistat-containing pharmaceutical composition with weight-losing function | |
| JPH07330593A (en) | Improve for fatigue | |
| CN107184598A (en) | A kind of pet heart disease composite tablet | |
| CN107050147B (en) | Composition for bidirectionally improving gastrointestinal tract function and losing weight and beautifying and preparation thereof | |
| CN102614253B (en) | Composition for nourishing and protecting liver and application of composition | |
| CN106728137A (en) | It is a kind of that the preparation method for preventing and treating hyperuricemia and gout medicine-food two-purpose monomer is extracted from coffee | |
| KR101992174B1 (en) | Tablet-type composition for preventing and relieving hangover, and protecting hepatic caused by alcohol containing medical herbs | |
| CN102462743A (en) | Traditional Chinese medicine composition with auxiliary protection effect on chemical liver injury and preparation method and application thereof | |
| CN106349318A (en) | Application of pentacyclic triterpene compounds to preparation of medicine for treating adiposis | |
| CN103040909B (en) | Tibetan medicine composition and application of composition in preparation of products for preventing and treating alcoholic liver diseases | |
| KR20040032821A (en) | Method for Reducing Muscle Fatigue through Administration of Adenosine Triphosphate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200922 |
|
| RJ01 | Rejection of invention patent application after publication |